Adcetris Indications/Uses

Hodgkin lymphoma: ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see Pharmacology: Pharmacodynamics under Actions).
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT; or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Systemic anaplastic large cell lymphoma: ADCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) (see Pharmacology: Pharmacodynamics under Actions).
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory sALCL.
Cutaneous T-cell lymphoma: ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see Pharmacology: Pharmacodynamics under Actions).